Advertisement

Topics

First patient receives BCX7353 dosing in BioCryst’s Phase II trial for HAE

19:00 EDT 3 Aug 2017 | Net Resources International

US-based BioCryst Pharmaceuticals has started dosing patients in the Phase II ZENITH-1 exploratory clinical trial of BCX7353 to treat patients with hereditary angioedema (HAE).

Original Article: First patient receives BCX7353 dosing in BioCryst’s Phase II trial for HAE

NEXT ARTICLE

More From BioPortfolio on "First patient receives BCX7353 dosing in BioCryst’s Phase II trial for HAE"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...